[Featured Stock] NextBio Aims for 15-Fold Revenue Growth by 2026... Targeting 40% Market Share in the US

Nextbiomedical is showing strong performance. It is partnering with Medtronic, a global medical device company with a market capitalization of 145 trillion won, to sell the endoscopic hemostatic agent 'Nexpowder' worldwide. Analysis suggesting that sales in 2026 will increase 15-fold compared to last year appears to be influencing the stock price.

As of 9:18 AM on the 22nd, Nexterpowder was traded at 29,400 won, up 5,700 won (24.05%) from the previous trading day.

It is expected that sales will rapidly increase as the market penetration rate of Nexpowder rises.

Jo Eun-ae, a researcher at LS Securities, explained, "Through a global licensing agreement with the major global medical device company Medtronic in 2020, sales began in Europe in 2021 and in the United States in 2023," adding, "We anticipate an increase in penetration rates within the hemostatic agent markets in the US and Europe, as well as a rise in market share within the powder product category."

Researcher Jo added, "In the second half of this year, with FDA approval for use in the colon (lower gastrointestinal tract), we expect an expansion of indications currently limited to the stomach."

He forecasted, "US sales volume will surpass that of Europe," and projected sales targets of 12 billion won this year, 37 billion won in 2025, and 76.2 billion won in 2026. The target sales volume for Nexpowder is assumed to increase from about 40,000 units this year to 310,000 units in 2026.

Researcher Jo emphasized, "The company's guidance for 2025 assumes a market share of 40% for Nexpowder."

Due to aging populations, increasing obesity, and lifestyle changes, demand for digestive endoscopy procedures and related devices is rising worldwide. The total number of endoscopic procedures globally reaches approximately 200 million cases.

This content was produced with the assistance of AI translation services.